COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,384 Articles (22,816 medRxiv, 8,568 bioRxiv)

Most recent first Previous |  Page 522: Articles 5211-5220  | Next

COVID-19 and Mental Health in China: Effects of Personality and Demographics
Zhang, X., Battisti, M., Proto, E.
10.1101/2023.01.20.23284600 — Posted: 2023-01-20
Elective Surgery Before, During and After the COVID-19 Pandemic in England 2015 - 2022: A Database Study
Remsing, S., Reeves, K., Evison, F., Morton, D., Chilton, P., Bird, P., Watson, S. I., Khunti, K., Lilford, R. J.
10.1101/2023.01.20.23284826 — Posted: 2023-01-20
Application of Elastic Net Regression for Modeling COVID-19 Sociodemographic Risk Factors
Moxley, T. A., Johnson-Leung, J., Seamon, E., Williams, C., Ridenhour, B. J.
10.1101/2023.01.19.23284288 — Posted: 2023-01-20
Extremely potent pan-sarbecovirus neutralizing antibodies generated by immunization of macaques with an AS03-adjuvanted monovalent subunit vaccine against SARS-CoV-2
Feng, Y., Yuan, M., Powers, J. M., Hu, M., Munt, J. E., Arunachalam, P. S., Leist, S. R., Bellusci, L., Adams, L. E., Sundaramurthy, S., Shirreff, L. M., Mallory, M. L., Scooby, T. D., Moreno, A., OHagan, D. T., Kleanthous, H., Villinger, F. J., Veesler, D., King, N. P., Suthar, M. S., Khurana, S., Baric, R. S., Wilson, I., Pulendran, B.
10.1101/2023.01.19.524784 — Posted: 2023-01-20
Induction of SARS-CoV-2 N-specific CD8+ T cell immunity in lungs by engineered extracellular vesicles associates with strongly impaired viral replication
Manfredi, F., Chiozzini, C., Ferrantelli, F., Leone, P., Pugliese, k., Spada, M., Di Virgilio, A., Giovannelli, A., Valeri, M., Cara, A., Michelini, Z., Andreotti, M., Federico, M.
10.1101/2023.01.19.524762 — Posted: 2023-01-20
Estimating The Uncertain Effect of the COVID Pandemic on Drug Overdoses
Moghtaderi, A., Zocchi, M., Pines, J., Venkat, A., Black, B.
10.1101/2023.01.19.23284772 — Posted: 2023-01-20
Trajectories of COVID-19: a longitudinal analysis of many nations and subnational regions
Burg, D., Ausubel, J. H.
10.1101/2023.01.19.23284768 — Posted: 2023-01-19
SARS-CoV-2 Omicron XBB.1.5 may be a cautionary variant by in silico study
Sugano, A., Kataguchi, H., Ohta, M., Someya, Y., Kimura, S., Maniwa, Y., Tabata, T., Takaoka, Y.
10.1101/2023.01.18.524660 — Posted: 2023-01-19
Effectiveness of Vaccination and Previous Infection Against Omicron Infection and Severe Outcomes in Children Under 12 Years of Age
Lin, D., Xu, Y., Gu, Y., Zeng, D., Wheeler, B., Young, H., Moore, Z., Sunny, S.
10.1101/2023.01.18.23284739 — Posted: 2023-01-19
The fourth dose of mRNA COVID-19 vaccine following 12 different three-dose regimens: Safety and immunogenicity to Omicron BA.4/BA.5
Kanokudom, S., Chansaenroj, J., Suntronwong, N., Assawakosri, S., Yorsaeng, R., Nilyanimit, P., Aeemjinda, R., Khanarat, N., Vichaiwattana, P., Klinfueng, S., Thongmee, T., Srimuan, D., Thatsanatorn, T., Sudhinaraset, N., Wanlapakorn, N., Honsawek, S., Poovorawan, Y.
10.1101/2023.01.19.23284761 — Posted: 2023-01-19

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).